VK2735 Tracker App
Track Your VK2735 Protocol — Injectable or Oral
VK2735 is Viking Therapeutics' investigational dual GLP-1/GIP agonist in both weekly-injectable and daily-oral forms. If you are in a trial or following the program, Shotlee is the free app to track doses, weight, and side effects in one place.
What Is VK2735?
VK2735 is Viking Therapeutics' dual GLP-1/GIP receptor agonist — the same two-incretin strategy as tirzepatide — developed in a once-weekly injectable (Phase 3 VANQUISH) and a once-daily oral tablet (Phase 2 VENTURE). It is investigational and only available within clinical trials.
Whether your protocol is injectable or oral, Shotlee tracks every dose, your weight trend, and side-effect severity so you have clean data to review with your study team or prescriber. Note: VK2735 is not FDA-approved and gray-market versions are unverified and unsafe.
What to Track in Shotlee
A complete VK2735 protocol record, whether you inject weekly or dose daily.
How to Track Your VK2735 Protocol
VK2735 Key Facts
Protocol FAQs
VK2735 is Viking Therapeutics' investigational dual GLP-1/GIP agonist for obesity, in injectable (Phase 3 VANQUISH) and oral (Phase 2 VENTURE) forms. It is not FDA-approved and is only available in clinical trials.
Open Shotlee, add VK2735 as your medication, and log each dose with amount and route. Track weight, titration, and side effects alongside. Reminders keep your schedule consistent.
Yes — tracking is completely free forever. Optional premium AI features are available.
Yes. Shotlee supports any route and frequency, so you can track the weekly injectable or the daily oral tablet, including dose changes over time.
No. VK2735 is investigational and only available in clinical trials. Any VK2735 sold by research-chemical vendors is unverified and unsafe.
Track Your VK2735 Protocol in Shotlee
Free dose logs, titration history, weight trends, and side-effect tracking — injectable or oral.
📚References & sources
Latest on VK2735
Viking Therapeutics Shares Surge 12% as Novo's CagriSema Stumbles
Shares of Viking Therapeutics surged approximately 12% on Monday following a clinical setback for Novo Nordisk's next-generation obesity drug CagriSema, which underperformed Eli Lilly's Tirzepatide in a pivotal Phase 3 trial. This shift highlights intensifying competition in the GLP-1 obesity market. Investors are eyeing Viking's VK2735 as a promising contender.
5 min read
Viking Therapeutics Stock Surges on VK2735 Trial Success
Viking Therapeutics stock closed at $34.34, up 11.44%, fueled by VK2735 Phase 2 success. The trial delivered 14.7% average weight reduction, challenging GLP-1 leaders like Ozempic. Acquisition speculation boosts investor interest.
1 min read